Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

Cencora, Inc. (COR)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $356.94 (close 2026-11-16); latest close $339.09 (2026-11-20), -5.0% since the report; figures re-marked at the latest close

Conclusion: WATCH

Conviction low · base case +47% · downside -18% · upside +57%

The market pays 0.23x TTM EV/Sales for Cencora, below the 0.31x peer median, while the business earns 18.6% ROIC against a 5.5% WACC and a 6.0% FCF yield; that spread is what the market is missing. The call is WATCH with low conviction: the 0.31x anchor rests on only three peers, and a 4.0% gross margin, about 66% top-10 customer concentration, $8.91B net debt and $1.09B TTM impairments leave little room for error. Downside is -21.8% to $279.18 on -5.0% sales at a compressed EV/Sales of 0.2x (today 0.23x). Base is +39.3% to $497.33 on EV/Sales at 0.31x, the peer median EV/Sales (3 peers in the comps table: MCK 0.31x, CAH 0.27x, IQV 3.31x). Upside is +49.0% to $531.84 on a re-rating to 0.31x on the cited dated catalyst.

Key numbers

  • Share price: $339.09
  • Market cap: $64.71B
  • Latest financial period: TTM to Jun 30, 2026
  • Revenue (TTM): $332.77B
  • EV / EBITDA (TTM): 18.1x
  • P/E (TTM): 24.7x
  • FCF yield: 6.3%
  • Price / book: 21.21x
  • Earnings-quality flags (TTM): Impairments -$1.09B (41% of net income)
  • P/E, adjusted (TTM): 17.5x
  • P/E, operating (tax-normalized) (TTM): 29.1x
  • EV / FCF (TTM): 18.2x
  • Revenue growth (latest fiscal year): +9.3%
  • ROIC (TTM): 18.6%
  • WACC: 5.5%
  • Economic profit spread: +13.2 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Cencora (formerly AmerisourceBergen) is a high-volume pharmaceutical sourcing and distribution business: FY2025 revenue was $321.33B against $11.48B of gross profit, i.e. low-margin distribution volume plus fee-based services to providers and manufacturers. Over the six fiscal years in the data, revenue rose from $189.89B (FY2020) to $321.33B (FY2025) and gross profit from $5.19B to $11.48B, while FY2020 was a loss year (operating income -$5.14B, net income -$3.41B). The TTM to 2026-06-30 shows $332.77B revenue, $3.04B operating income, $2.62B net income and $4.82B operating cash flow, with pre-tax income ($3.61B) running above operating income, so part of the TTM bottom line is non-operating and not broken out in these sources. Between the FY2020 and FY2025 Item 1 descriptions the business purpose is essentially unchanged; the name changed to Cencora and the services language expanded.

  2. ✓ 2. Competitive advantage

    Cencora's advantage is distribution scale and cost, not brand or pricing power: management believes it has one of the lowest operating cost structures among pharmaceutical distributors, but FY2025 gross profit was $11.48B on $321.33B of revenue and operating income was $2.63B. Operating income was roughly flat at $2.18B-$2.63B in FY2021-FY2025, and FY2020 had a $5.14B operating loss. Competition is intense from McKesson, Cardinal, UPS Logistics and direct/alternative channels, while top-10 customers were about 66% of FY2025 revenue.

  3. ✓ 3. 10-Q takeaways

    The latest 10-Q in the source set is Q3 FY2026 (quarter ended June 30, 2026): revenue rose 5.1% to $84.8B, gross margin was 4.26% (+66 bps), and operating income was $1.1B (+29.1%), with the quarter's opioid-litigation credit and nine-month OneOncology remeasurement gain kept outside operating comparisons. Nine-month operating cash flow improved to $1.7B, Q3 buybacks were $1B, and FY2026 adjusted EPS guidance was raised to $17.75-$17.95. The 10-Q risk-factor section points back to the FY2025 10-K; the source's computed risk-factor diff is for that 10-K, not the 10-Q.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans